Contraline erects $7.2M for contraceptive implants for men
The cervical industry has had contraceptive implants since the late 1960s, but there hasn’t been much competition to slow the fallopian swim team at their source. In fact, Contraline It claims to be the first major innovation in this field since human vasectomy about 125 years ago. The company calls its product ADAM, and it just raised cash to continue its experiments.
“The first-of-its-kind human male contraceptive implant is a major clinical milestone that opens new possibilities for men who want to take contraception into their own hands,” said Kevin Eisenfrats, co-founder and CEO of Contraline. “Patient demand for the ADAM study has been phenomenal, surpassing the number of participants in the entire trial within three weeks of opening registration. We look forward to advancing ADAM through clinical development and bringing this product to market to change the way people think about contraception.”
The company just raised $7.2 million in funding led by GV. The goal is to advance human clinical trials of an injectable hydrogel designed to provide long-acting, non-permanent contraception to men. The product uses a “hydrogel” designed to block the flow of sperm through the vas deferens for a predetermined period of time, eventually causing it to deteriorate and thus offering a non-permanent contraceptive option.
The company suggests that the contraceptive is long-acting but not permanent, and claims that it has no hormonal effect on female patients. The company told TechCrunch that four men were implanted with ADAM at a hospital in Australia, using a minimally invasive, no-scalpel approach, with ADAM injected using a patent-pending delivery device.
The procedure represents the first patient to be transplanted into the ‘ADAM study’, which is performed with the approval of the Human Research Ethics Committee. The ADAM Study is evaluating the safety of ADAM Hydrogel, while monitoring study subjects’ semen parameters over a three-year period.
“Contraline has the potential to revolutionize the contraceptive market,” said Kathy Friedman, GV Executive Partner. “We look forward to working with the team as they continue to develop a long-acting, reversible male contraceptive that empowers more people with more choices in terms of family planning.”
The Contraline study is continuing in Australia, and its next long-term goal is to conduct a second study with a larger group of patients in the United States.
Contraline makes $7.2 million for male contraceptive implants by Hajj Jean Camps Originally Posted in Take Crunch